Evidence map›Paper›PMID 30352909›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Leveraging Bioorthogonal Click Chemistry to Improve

Sophie Poty, Lukas M Carter, Komal Mandleywala, Rosemery Membreno, Dalya Abdel-Atti, Ashwin Ragupathi, Wolfgang W Scholz, Brian M Zeglis, Jason S Lewis

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 101 citations in OpenAlex.

  1. Review
  2. Progress in the application ofAnnals of nuclear medicine · 2026
    Review
  3. Delta-like Ligand 3-DirectedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  9. Review
  10. Radiances of Cerenkov-Emitting Radionuclides on the In Vivo Imaging System.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  11. Article
  12. Review
  13. Toward Realization of Bioorthogonal Chemistry in the Clinic.Topics in current chemistry (Cham) · 2025
    Review
  14. Review
  15. Article
  16. Examination of the PET in vivo generatorEuropean journal of nuclear medicine and molecular imaging · 2024
    Article
  17. Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sophie PotyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. lewisj2@mskcc.org bz102@hunter.cuny.edu potys@mskcc.org.ORCID 0000-0002-5496-0758
Lukas M CarterDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4848-4190
Komal MandleywalaDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Rosemery MembrenoDepartment of Chemistry, Hunter College of the City University of New York, New York, New York.
Dalya Abdel-AttiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ashwin RagupathiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Wolfgang W ScholzMabVax Therapeutics, San Diego, California.
Brian M ZeglisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. lewisj2@mskcc.org bz102@hunter.cuny.edu potys@mskcc.org.
Jason S LewisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. lewisj2@mskcc.org bz102@hunter.cuny.edu potys@mskcc.org.ORCID 0000-0001-7065-4534
Memorial Sloan Kettering Cancer Center · USThe Graduate Center, CUNY · USMabvax Therapeutics (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Pretargeted Clinical Imaging of CA19.9 in Pancreatic CancerU01CA221046 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ZEGLIS, BRIAN MATTHEW · 2018 to 2022
$3.5M
Biomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9M
Pretargeted Radioimmunotherapy Based on Bioorthogonal Click ChemistryR00CA178205 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2015 to 2017
$747k
Development of a Novel Peptide Platform for Targeted PET Imaging and Radiotherapy of Breast CancerF32EB025050 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI CARTER, LUKAS MICHAEL · 2017 to 2019
$179k
NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA178205NCI NIH HHS R01 CA172546NCI NIH HHS U01 CA221046NIBIB NIH HHS F32 EB025050
6 · The paper itself

Abstract

purposeInterest in targeted alpha-therapy has surged due to α-particles' high cytotoxicity. However, the widespread clinical use of this approach could be limited by on-/off-target toxicities. Here, we investigated the inverse electron-demand Diels-Alder ligation between an

resultsA comparative biodistribution study of the PRIT versus RIT methodology underscored the improved pharmacokinetic properties (e.g., prolonged tumor uptake and increased tumor-to-tissue ratios) of the PRIT approach. Cerenkov imaging coupled to PRIT confirmed the

conclusionsThe ability of

Indexed as

Click ChemistryActiniumAnimalsAntineoplastic AgentsCarcinoma, Pancreatic DuctalCell Line, TumorDisease Models, AnimalDose-Response Relationship, DrugDose-Response Relationship, RadiationHumansImmunoconjugatesMiceMolecular ImagingPancreatic NeoplasmsRadiometryRadiopharmaceuticalsActiniumActinium-225Antineoplastic AgentsImmunoconjugatesRadiopharmaceuticals

Identifiers

PMID30352909
PMCPMC6343144
OpenAlexW2895961520

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.